Dr. Robyn Young, M.D.
What this data tells you about Dr. Young
Dr. Robyn Young is a hematology & oncology specialist in Fort Worth, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Young performed 8,937 Medicare services across 1,151 unique beneficiaries.
Between the years covered by Open Payments, Dr. Young received a total of $107,539 from 66 pharmaceutical and/or device companies across 446 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Young is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,020 | $19 | $40 |
| Dexamethasone injection (steroid) | 980 | $0 | $5 |
| Anti-nausea injection (Aloxi/palonosetron) | 830 | $1 | $52 |
| Office visit, established patient (30-39 min) | 536 | $87 | $275 |
| Injection, zoledronic acid, 1 mg | 424 | $6 | $300 |
| COVID-19 test, self-administered | 340 | $12 | $30 |
| Office visit, established patient, complex (40-54 min) | 316 | $131 | $350 |
| Injection of additional new drug or substance into vein | 223 | $12 | $70 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 166 | $47 | $160 |
| Drug injection, under skin or into muscle | 148 | $10 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 125 | $99 | $409 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 118 | $45 | $190 |
| Injection, diphenhydramine hcl, up to 50 mg | 82 | $1 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 78 | $22 | $100 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 70 | $1 | $5 |
| Ct scan of chest with contrast | 56 | $52 | $401 |
| Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | 56 | $36 | $120 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 46 | $25 | $90 |
| Office visit, established patient (20-29 min) | 45 | $58 | $175 |
| Nuclear medicine study of bone and/or joint whole body | 40 | $182 | $800 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 39 | $48 | $125 |
| CT scan of abdomen and pelvis with contrast | 36 | $137 | $681 |
| Hospital follow-up visit, moderate complexity | 30 | $62 | $175 |
| New patient office visit, complex (60-74 min) | 24 | $170 | $500 |
| Administration of chemotherapy into vein, each additional hour | 23 | $22 | $93 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 22 | $106 | $450 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 21 | $1,160 | $4,069 |
| Chronic care management, first 20 min/month | 16 | $48 | $161 |
| Advance care planning consultation, first 30 min | 14 | $61 | $250 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $52 | $150 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (84%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for hematology & oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Young is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 6% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Young experienced with denosumab injection (prolia/xgeva)?
Does Dr. Young receive payments from pharmaceutical companies?
How do Dr. Young's costs compare to other hematology & oncology specialists in Fort Worth?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology